The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma

Goldstraw, Peter; Rami‐Porta, Ramón; Asamura, Hisao; Ball, David; Beer, David G.; Beyruti, Ricardo; Bolejack, Vanessa; Chansky, Kari; Crowley, John; Detterbeck, Frank C.; Eberhardt, Wilfried Ernst Erich; Edwards, John; Giroux, Dorothy J.; Gleeson, Fergus; Groome, Patti A.; Huang, James; Kennedy, Catherine; Kim, Young Tae; Kingsbury, Laura; Kondo, Haruhiko; Krasnik, Mark; Kubota, Keiichi; Lerut, Toni; Lyons, Gustavo; Marino, Mirella; Marom, Edith M.; Mitchell, Alan; Nicholson, Andrew G.; Peake, Michael; Rice, Thomas W.; Rosenzweig, Kenneth E.; Saijo, Nagahiro; Schil, Paul Van; Sculier, Jean-Paul; Shemanski, Lynn; Stratton, Kelly; Suzuki, Kenji; Tachimori, Yuji; Travis, William D.; Tsao, Ming Sound; Turrisi, Andrew; Vansteenkiste, Johan; Watanabe, Hirokazu; Wu, Yi‐Long; Baas, Paul; Erasmus, Jeremy J.; Hasegawa, Seiki; Inai, Kei; Kernstine, Kemp H.; Krug, Lee M.; Nackaerts, Kristiaan; Falkson, Conrad; Filosso, Pier Luigi; Giaccone, Giuseppe; Kondo, Kazuya; Lucchi, Marco; Okumura, Meinoshin; Blackstone, Eugene H.; Batırel, Hasan Fevzi; Billè, Andrea; Pastorino, Ugo; Call, Sergi; Cangır, Ayten; Cedrés, S.; Friedberg, Joseph S.; Galateau-Sallé, Françoise; Hasagawa, S.; Kindler, Hedy L.; McCaughan, Brian C.; Nakano, Takashi; Nowak, Adriana; Öztürk, C. Atinkaya; Pass, Harvey I.; Perrot, Marc de; Rea, Federico; Rice, David C.; Rintoul, Robert C.; Ruffini, Enrico; Rusch, Valerie W.; Spaggiari, Lorenzo; Galetta, Domenico; Syrigos, K.; Thomas, Charles F.; Meerbeeck, Jan P. van; Nafteux, Philippe; Weder, Walter; Optiz, I.; Yoshimura, Masahiro

doi:10.1016/j.jtho.2016.09.124

Cited by 189 publications

(121 citation statements)

References 8 publications

Supporting

Mentioning

116

Contrasting

Unclassified

Order By: Relevance

“…In 2016, the International Association for the Study of Lung Cancer (IASLC) Staging Committee published proposals for the revisions of the T, N and M descriptors for the eighth edition of the TNM classification of MPM 11 . This was an international, multi-institutional cohort study.…”

Section: Section 4: Staging Systemsmentioning

confidence: 99%

British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma

Woolhouse

Bishop

Darlison

et al. 2018

Thorax

Self Cite

181

219

View full text Add to dashboard Cite

Section: Section 4: Staging Systemsmentioning

confidence: 99%

British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma

Woolhouse

Bishop

Darlison

et al. 2018

Thorax

Self Cite

181

219

View full text Add to dashboard Cite

“…In addition, sensitive and specific biomarkers for MPM are urgently needed for screening of asbestos-exposed subjects, since early diagnosed patients may benefit a better survival through a more effective multimodality therapy (surgery combined with radiotherapy and chemotherapy) (66,67). Nevertheless, biomarkers for routinely early diagnosis and screening are not available yet.…”

Section: Discussionmentioning

confidence: 99%

Biomarkers in the prevention and follow-up of workers exposed to asbestos

Foddis¹,

Bonotti²,

Landi³

et al. 2018

J. Thorac. Dis.

View full text Add to dashboard Cite

Although in most developed countries the use of asbestos is banned, there is still a consistent portion of the world where asbestos extraction, trading and manufacturing of asbestos-made products is largely diffuse. Worldwide, hundreds of millions of people are at risk of developing an asbestos caused disease because of occupational, environmental or domestic exposure. The WHO estimates that asbestos is responsible for more than 100,000 deaths yearly. This scenario has prompted the research on biomarkers potentially useful for early diagnosis, prognosis and preventive programs on exposed population as well. Here we reviewed the up-to-date literature on this field of research highlighting that along with mesothelin and osteopontin (OPN), some more recently investigated molecules, such as high mobility group box 1 (HMGB1) protein, fibulin-3 and some miRNAs showed very promising. Most of the carried-out studies showed an interesting diagnostic and prognostic performance of some biomarkers, but since they usually lack adequate either specificity or sensitivity, their use in screening or in preventive programs is still not recommended on a routine basis. However, this review suggests the need for more reliable experimental design involving larger population and preferring longitudinal screening of asbestos exposed individuals rather than a single baseline assessment investigation. In addition, given their better diagnostic accuracy, the use of panels including several biomarkers is highly recommended.

show abstract

“…MM is mostly diagnosed at an advanced stage when it is poorly responsive to the current therapies and it was demonstrated that early diagnosis significantly improves overall survival (5,29,30). However, the currently available tissue and serological diagnostic biomarkers are characterized by relatively poor sensitivity and specificity preventing the use of reliable tools both for identification of individuals exposed to asbestos and other carcinogenic fibers and for early detection in patients who are developing MM (109).…”

Section: Discussionmentioning

confidence: 99%

“…Monotherapy and combination therapy have been widely investigated for the treatment of MM however, all therapeutic strategies failed to significantly benefit patients so far (25)(26)(27)(28). On the other hand, it has been shown that when patients are diagnosed and treated at an early stage (stage I) of MM, the overall median survival is significantly improved (29,30). Therefore, the relevance of early diagnosis of MM is very high for a better response to therapy.…”

Section: Review Articlementioning

confidence: 99%

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update

Chen

Gaudino

Pass

et al. 2017

Transl. Lung Cancer Res.

Self Cite

View full text Add to dashboard Cite

Malignant mesothelioma (MM) is an aggressive and lethal cancer, mostly related to inhalation of asbestos and erionite fibers. MM is associated with poor prognosis, because of its resistance to current therapies, even if higher survival occurs in patients diagnosed and treated when at stage I of the disease.However, these do not exceed 5% of the total number of cases, due to the inadequacy of the existing biomarkers for early and accurate diagnosis. Therefore, new effective biomarkers are needed for MM detection at earlier stages and to develop tailored therapies. Here we review the most promising biomarkers in MM to date: mesothelin, soluble mesothelin-related peptides (SMRPs), megakaryocyte potentiating factor (MPF), Osteopontin (OPN), Fibulin-3, high mobility group B1 (HMGB1), microRNAs (miRNAs), multiplex protein signatures. The validation of these biomarkers will allow their use, alone or in combination, for monitoring individuals from cohorts at risk of MM and attaining early detection of MM that is instrumental in improving patient survival.

show abstract

The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma

Abstract: This first evidence-based revision of the TNM classification for MPM leads to substantial changes in the T and N components and the stage groupings.

Cited by 189 publications

References 8 publications

British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma

British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma

Biomarkers in the prevention and follow-up of workers exposed to asbestos

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update

Contact Info

Product

Resources

About